Key clinical point: For elderly patients with chronic lymphocytic leukemia and comorbidities, the anti-CD20 monoclonal antibody ofatumumab may be a safe and effective treatment option.
Major finding: The overall response rate was 72%.
Study details: A phase 2 trial involving 34 elderly patients with chronic lymphocytic leukemia.
Disclosures: The study was funded by Novartis, which markets the antibody. The investigators reported additional relationships with AbbVie, Roche, Celgene, and others.
Vitale et al. J Geriatr Oncol. 2019 Apr 18. doi: 10.1016/j.jgo.2019.04.002.